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Background. Estimation of glomerular filtration rate (eGFR) from biomarkers has evolved and multiple equations are available to
estimate renal function at bedside. Methods. In a random sample of 119 Uruguayans (54.5% women; 56.2 years (mean)), we used
Bland and Altman’s method and Cohen’s kappa statistic to assess concordance on a continuous or categorical (eGFR < 60 versus
≥60mL/min/1.73m2) scale between eGFRcys (reference) and eGFR derived from serum creatinine according to the Modification
of Diet in Renal Disease (eGFRmdrd) or the Chronic Kidney Disease Epidemiology Collaboration equations (eGFRepi) or from
both serum cystatin C and creatinine (eGFRmix). Results. In all participants, eGFRmdrd, eGFRepi, and eGFRmix were, respectively,
9.7, 11.5, and 5.6mL/min/1.73m2 higher (𝑃 < 0.0001) than eGFRcys. The prevalence of eGFR <60mL/min/1.73m
2 was the highest
for eGFRcys (21.8%), intermediate for eGFRmix (11.8%), and the lowest for eGFRmdrd (5.9%) and eGFRepi (3.4%). Using eGFRcys as
reference, we found only fair agreement with the equations based on creatinine (Cohen’s kappa statistic 0.15 to 0.23). Conclusion.
Using different equations we reached clinically significant differences in the estimation of renal function. eGFRcys provides lower
estimates, resulting in higher prevalence of eGFR <60mL/min/1.73m2.
1. Introduction
The glomerular filtration rate (GFR) is the most widely used
indicator of overall renal function.TheGFR can bemeasured
by clearance of an ideal, usually exogenous, filtration marker
such as inulin, iothalamate, EDTA, diethylene triamine
pentaacetic acid, or iohexol. The clearance of endogenous
markers such as creatinine or blood urea nitrogen can
overestimate or underestimate the GFR. All these methods
have the drawback to be complex and require 24-hour urine
collection, which is not always practicable in day-to-day
clinical practice. A more pragmatic approach is to estimate
GFR from equations based on serum creatinine [1, 2].
More recently, experts proposed cystatin C as an alter-
native to creatinine [3]. Cystatin C is a nonglycosylated
protein with low molecular mass (13.3 kDa) generated by
all nucleated cells of the body at a constant rate, is freely
filtered by the glomerulus, and is not secreted by renal tubules
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but completely reabsorbed with subsequent degradation by
proximal tubular cells [4, 5]. For those properties cystatin C
is an endogenous surrogate of GFR. Compared with serum
creatinine, cystatin C levels are less dependent on ethnicity,
sex, age, and muscle mass or protein intake. Moreover, as
serum creatinine, cystatin C is an independent predictor of
cardiovascular and overall mortality [6].
Compared toGFRmeasurement based on the renal clear-
ance of exogenous markers, estimated glomerular filtration
rate (eGFR) is more precise if derived from both cystatin
C and creatinine levels in serum [3]. This observation was
consistent across sex, age, and diabetes mellitus [7]. On the
other hand, measurement of cystatin C is costly and eGFR
based on cystatin C needs further validation across a broad
spectrum of populations with or without chronic kidney
disease. The purpose of our current study was to compare
estimates of eGFR based on cystatin C and creatinine in
randomly recruited Uruguayans, using eGFR derived from
cystatin C as reference.
2. Materials and Methods
2.1. Study Population. GEnotipo Fenotipo y Ambiente de la
HiperTension en UruguaY (GEFA-HT-UY) is a prospective
cohort study started inApril 2012 conducted by theUnidad de
Hipertensio´nArterial, Hospital deCl´ınicasDr.ManuelQuin-
tela, Universidad de la Repu´blica, Montevideo, Uruguay [8].
The Ethics Committee of the University Hospital approved
the study protocol and all participants gave informed written
consent. The aim of the study is to explore the relation
of blood pressure with genetic and environmental factors
in a representative Uruguayan population sample. Nuclear
families were randomly recruited from the inhabitants of a
geographically defined area, the Juana de Ame´rica housing
project, located about 10 km from downtown Montevideo.
A nuclear family had to include at least one parent and
two siblings. The minimum age was 18, without upper age
limit. Family members living at the same address or within
a distance of no more than 10 km were eligible. We invited
participants by telephone. The participation rate among
eligible subjects was 72.7%. In November 2013, 149 people
had participated, of whom we excluded 30 from the present
analysis, because either cystatin C or creatinine had not been
measured (𝑛 = 22) or because they had not yet completed
the physical examination (𝑛 = 8). Thus, the number of
participants analysed statistically totalled 119.
2.2. FieldWork. The examinations took place at a field centre
locatedwithin the neighbourhood. Trained observers admin-
istered a standardised questionnaire inquiring into each
participant’s medical history, smoking and drinking habits,
and intake of medications. They measured blood pressure
according to the European guidelines. After participants had
rested for 5 minutes in the sitting position, the observers
obtained five consecutive blood pressure readings (phase V
diastolic pressure) to the nearest 2mmHg, using mercury
sphygmomanometers. Standard cuffs had a 12 × 24 cm inflat-
able portion, but if upper arm girth exceeded 31 cm, larger
cuffs with 15 × 35 cm bladders were used. Pulse pressure
is the difference of systolic minus diastolic blood pressure.
Mean arterial pressure is diastolic pressure plus one-third of
pulse pressure. For analysis, the five blood pressure readings
were averaged. Hypertension was an office blood pressure of
at least 140mmHg systolic or 90mmHg diastolic or use of
antihypertensive drugs.The observers measured body height
to the nearest 0.5 cm with a pliable measurer and the partici-
pant standing against the wall. Participants wore light indoor
clothing without shoes for body weight measurements. Body
mass index was weight in kilograms divided by square of
height in meters. Venous blood samples were obtained after
at least 12 hours fasting and were kept at 4∘C and within
2 hours period were analysed for serum levels of cystatin
C, creatinine, cholesterol, and glucose. Diabetes mellitus
was the use of anti-diabetic drugs or a fasting glucose ≥
126mg/dL (7mmol/L).
2.3. Arterial Phenotypes. After the participants had rested
15min in the supine position, we recorded during an 8 s
period the radial waveforms at the right side by applanation
tonometry. We used a high-fidelity SPC-301 micromanome-
ter (Millar Instruments, Houston, TX) interfaced with a
computer running SphygmoCor software, version 8.2 (AtCor
Medical, West Ryde, New South Wales, Australia). We dis-
carded recordings when the systolic or diastolic variability
of consecutive waveforms exceeded 5% or the amplitude of
the pulse wave signal was less than 80mV. We calibrated the
radial pulse wave on the brachial blood pressure [9]. From
the radial signal, the SphygmoCor software calculates the
aortic pulse wave bymeans of a validated generalised transfer
function [10, 11]. The augmentation index was the ratio of the
second to the first peak of the pressure wave expressed as a
percentage.
Aortic pulse wave velocity was measured by sequential
ECG-gated recordings of the arterial pressure waveform
at the carotid and femoral arteries [12]. We measured the
distances from the suprasternal notch to the carotid sampling
site (distance 𝐴) and from the suprasternal notch to the
femoral sampling site (distance 𝐵). Pulse wave travel distance
was calculated as distance 𝐵 minus distance 𝐴. Pulse transit
time was the average of 10 consecutive beats. Pulse wave
velocity was the distance inmeters divided by the transit time
in seconds [12].
2.4. Laboratory Methods. Serum cystatin C was measured
by a particle-enhanced turbidimetric immunoassay (PETIA),
(COBAS, Roche diagnostics, Germany). The latex enhanced
particles coated with anticystatin C antibodies in the reagent
agglutinate with the human cystatin C in the sample. The
degree of the turbidity caused by the aggregate was deter-
mined turbidimetrically at 546 nm.This assay has a detection
limit of 0.4mg/L and a coefficient of variation of 1.3%. Serum
creatinine was measured by modified kinetic Jaffe´ methods
with the modifications described elsewhere [13, 14]. The
detection limit is 0.17mg/dL and the coefficient of variation
was 1.6%. We use a creatinine method that has calibration
traceable to an IDMS reference measurement procedure
according to present recommendations [15, 16].
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2.5. Estimated Glomerular Filtration Rate. We estimatedGFR
using four equations. First, we computed eGFR from serum
cystatin C eGFRcys, as described by Inker and colleagues [3].
Next, we calculated eGFR from serum creatinine according
to the IDMS-traceable MDRD Study Equation (MDRD)
[17, 18] formula (eGFRmdrd) or the Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI) [2] equation
(eGFRepi). Finally, as proposed by Inker and colleagues, [3]
we also derived eGFR from both serum cystatin C and
serum creatinine (eGFRmix). All aforementioned estimates
[1–3] account for sex and age and with the exception of
eGFRcys also consider ethnicity (black versus nonblack).
This particular characteristic was irrelevant for our current
study as our participants only included Whites mainly
of European descent. Table S1 in the online data supple-
ment provides detailed information on each formula (see
Table S1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2014/837106). In our current anal-
yses, we compared findings based on the various methods
to estimate GFR against eGFRcys as the referent method.
Low glomerular filtration rate (L-GFR) was an eGFR <
60mL/min/1.73m2 based on a single determination of each
biomarker.
2.6. Statistical Analysis. For database management and sta-
tistical analysis, we used SAS software, version 9.3 (SAS
Institute, Cary, NC). First, in exploratory analyses, we
assessed the characteristics of participants by fourths of
the distribution of eGFRcys. For comparison of means and
proportions, we applied Student’s t-test (or ANOVA) and
the 𝜒2 statistic, respectively. We assessed agreement between
paired measurements on a continuous scale by Bland and
Altman’s method [19]. To allow comparison with literature
data, we also computed correlation coefficients. The National
Kidney Foundation KDOQI guideline proposes a threshold
of 60mL/min/1.73m2 to diagnose chronic kidney disease
[20]. In categorical analyses, we, therefore, also assessed the
agreement between equations to dichotomize subjects in L-
GFR or not-L-GFR using Cohen’s kappa statistic [21]. A
kappa value of 0.20 or less indicates slight agreement, 0.20
to 0.40 fair agreement, 0.41 to 0.60 moderate agreement,
0.61 to 0.80 substantial agreement, and 0.81 to 1.00 almost
perfect agreement. We studied the association between the
four definitions of eGFR dichotomized at 60mL/min/1.73m2
in hypertensive and diabetic subjects by McNemar’s test
for paired comparisons of proportions. Because of the low
frequencies in some cells, we applied exact statistics in
two-by-two tables. Finally, we assessed the added capacity
of eGFRcys to differentiate between normotension versus
hypertension or between people with or without diabetes
mellitus, using the integrated discrimination improvement
(IDI) and the net reclassification improvement (NRI) [22, 23].
Statistical significance was an 𝛼 level of 0.05.
3. Results
3.1. Characteristics of Participants. The 119 participants
included 68 women (57.1%) and 53 (44.5%) hypertensive
patients, of whom 35 (66.0%) were on antihypertensive drug
treatment. Among 68 women and 51 men, 11 (16.2%) and
5 (9.8%) were smokers; 21 women (30.1%) and 32 men
(62.7%) reported intake of alcohol. In smokers, median
tobacco use was 10 cigarettes per day (interquartile range,
6–15). In drinkers, the median alcohol consumption was
8 g per day (interquartile range, 4–54). In the whole study
population, age (SD) averaged was 56.5 (17.3) years and
systolic and diastolic blood pressure 126.5 (19.6)mmHg and
79.6 (11.7)mmHg, respectively. Based on a self-report of
the main maternal and paternal background, 37 participants
(31.1%) reported a mixture of Caucasian, African, or Native-
American, while 82 participants (68.9%) reported coincident
Caucasian background.
Among all participants, serum cystatin C and serum
creatinine averaged from 0.99 (0.22) mg/L to 0.81 (0.21)
mg/dL with no difference between women and men for
cystatin C (0.99 versus 1.00mg/L; 𝑃 = 0.77), whereas
women had lower serum creatinine than men had (0.72
versus 0.93mg/dL; 𝑃 < 0.0001). In all participants, mean
values were 80.0 (23.8)mL/min/1.73m2 for eGFRcys, 89.7
(22.5)mL/min/1.73m2 for eGFRmdrd, 91.5 (19.0)mL/min/
1.73m2 for eGFRepi, and 85.6 (20.2)mL/min/1.73m
2 for
eGFRmix, with no sex differences (𝑃 ≥ 0.23).
Table 1 provides the characteristics of participants by
fourths of the distribution of eGFRcys, which was used as
reference. The prevalence of hypertension (𝑃 = 0.027), age
(𝑃 < 0.0001), and systolic blood pressure (𝑃 = 0.0097),
but not diastolic blood pressure (𝑃 = 0.79) or mean arterial
pressure (𝑃 = 0.18) increased (𝑃 = 0.027) with lower eGFRcys
category. The central systolic augmentation index and aortic
pulse wave velocity also rose (𝑃 < 0.0001) across decreasing
fourths of the eGFRcys distribution. Trends in eGFRmdrd,
eGFRepi, and eGFRmix ran in parallel with the distribution of
eGFRcys.
3.2. Concordance between Estimates of GFR on a Contin-
uous Scale. Figure 1 shows the Bland and Altman plots
comparing eGFRmdrd, eGFRepi, and eGFRmix, with eGFRcys
as the referent method. Table 2 shows the mean devia-
tions of eGFRmdrd, eGFRepi, and eGFRmix from eGFRcys.
In all participants, eGFRmdrd, eGFRepi, and eGFRmix were,
respectively, 9.7, 11.5, and 5.6mL/min/1.73m2 higher than
eGFRcys. The corresponding ±2 SD intervals expressed in
mL/min/1.73m2 (Figure 1) ranged from −38.5 to +57.9 for
eGFRmdrd, −25.5 to +48.5 for eGFRepi, and −10.2 to +21.4 for
eGFRmix, and the corresponding correlation coefficients were
−0.04 (𝑃 = 0.69), −0.26 (𝑃 = 0.0046), and −0.40 (𝑃 <
0.0001), respectively. Analyses stratified according to sex,
age, normotension versus hypertension, and absence versus
presence of diabetes mellitus were consistent with those in all
participants (Table 2). Figure 2 shows that across fourths of
the distribution of eGFRcys, eGFRmdrd, eGFRepi, and eGFRmix
were consistently higher (𝑃 < 0.002) than eGFRcys except in
the highest category of eGFRcys (𝑃 = 0.25).
3.3. Concordance between Estimates of GFR on a Categorical
Scale. The prevalence of L-GFR was the highest for eGFRcys,
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Table 1: Characteristics of 119 participants by fourths of the distribution of eGFRcys.
Characteristic Categories of eGFRcys 𝑃
eGFRcys limits, mL/min/1.73m
2
>93.7 93.7–78.7 78.7–61.5 ≤61.5 ⋅ ⋅ ⋅
Number of subjects (%) 30 30 30 29 ⋅ ⋅ ⋅
Women 18 (60.0) 22 (73.3) 12 (40.0) 16 (53.3) 0.063
Smokers 4 (13.3) 5 (16.7) 3 (10.0) 4 (13.8) 0.90
Drinking alcohol 16 (53.3) 13 (43.3) 12 (40.0) 12 (41.4) 0.73
Hypertension 8 (26.7) 11 (36.7) 16 (53.3) 18 (62.1) 0.027
Antihypertensive treatment 3 (10.0) 8 (26.7) 12 (40.0) 12 (66.6) 0.32
Cardiovascular disease 2 (6.7) 1 (3.3) 3 (10.0) 2 (6.9) 0.87
Diabetes mellitus 4 (13.3) 1 (3.3) 7 (23.3)∗ 8 (27.6) 0.058
Mean (SD) of characteristic
Age, years 41.3 (14.0) 52.1 (14.7)† 64.2 (13.9)† 68.9 (11.8) <0.0001
Body mass index, kg/m2 27.6 (4.4) 29.2 (5.1) 29.1 (5.3) 29.5 (4.6) 0.44
Office blood pressure
Systolic pressure, mmHg 118.5 (15.1) 123.3 (16.6) 130.9 (21.1) 133.6 (22.0) 0.0097
Diastolic pressure, mmHg 79.3 (10.6) 78.2 (11.9) 79.8 (12.1) 81.4 (12.7) 0.79
Pulse rate, beats per minute 71.3 (7.1) 69.1 (9.9) 75.4 (8.9)∗ 71.0 (9.8) 0.054
Central augmentation index, % 14.7 (14.8) 19.6 (11.3) 28.7 (9.8)† 23.6 (10.9) <0.0001
Aortic pulse wave velocity, m/s 7.6 (1.8) 8.6 (2.5) 11.1 (3.2)† 10.0 (2.9) <0.0001
Biochemical measurements
Total cholesterol (mg/dL) 204.2 (30.2) 194.6 (28.8) 216.5 (38.6)∗ 225.3 (34.9) 0.004
Glucose (mg/dL) 100.0 (35.3) 96.6 (12.7) 101.8 (21.6) 101.9 (15.6) 0.88
Serum cystatin C (mg/L) 0.75 (0.15) 0.94 (0.05)§ 1.03 (0.07)§ 1.27 (0.14)§ <0.0001
Serum creatinine, mg/dL 0.75 (0.14) 0.81 (0.15) 0.77 (0.28) 0.92 (0.23)∗ 0.0077
eGFRmdrd, mL/min/1.73m
2 103.2 (21.6) 92.9 (16.1)∗ 90.1 (24.5) 71.9 (5.4)† <0.0001
eGFRepi, mL/min/1.73m
2 107.1 (14.2) 96.4 (12.8)† 88.6 (17.1)∗ 73.4 (14.1)‡ <0.0001
eGFRmix, mL/min/1.73m
2 110.4 (13.1) 90.7 (7.0)§ 78.6 (8.6)§ 61.8 (9.2)§ <0.0001
eGFRcys, eGFRmdrd, eGFRepi, and eGFRmix indicate estimated glomerular filtration rate derived from serum cystatin C, from serum creatinine according to
the IDMS-traceable Modification of Diet in Renal Disease (MDRD) Study Equation or the Chronic Kidney Disease Epidemiology Collaboration equations, or
from both serum cystatin C and creatinine. Office blood pressure was the average of five consecutive readings. Hypertension was an office blood pressure of
≥140mmHg systolic or ≥90mmHg diastolic or use of antihypertensive drugs. Diabetes mellitus was a fasting glucose level of ≥126mg/dL or use of antidiabetic
drugs. The central augmentation index was standardised to a heart rate of 75 beats/minute. Conversion factors: creatinine from mg/dL to 𝜇mol/L, multiply
by 88.4; cholesterol from mg/dL to mmol/L, multiply by 0.0259. 𝑃 values denote the significance of the differences in prevalence or means across quartiles of
eGFRcys. Significance of the difference with the adjacent lower fourth:
∗
𝑃 ≤ 0.05; †𝑃 ≤ 0.01; ‡𝑃 ≤ 0.001; §𝑃 ≤ 0.0001.
intermediate for eGFRmix, and the lowest for eGFRmdrd and
eGFRepi (Table 3). Using eGFRcys as reference, Cohen’s kappa
statistic was 0.230 (95% confidence interval [CI], 0.036 to
0.427; 𝑃 = 0.0005) for eGFRmdrd, 0.151 (CI, −0.021 to 0.322;
𝑃 = 0.032) for eGFRepi, and 0.587 (CI, 0.399 to 0.775; 𝑃 <
0.0001) for eGFRmix.
3.4. Association between Chronic KidneyDisease and Response
Variables. Among 53 hypertensive patients, the prevalence
of L-GFR was higher (𝑃 < 0.0001) if patients were catego-
rized based on eGFRcys (17 patients, 32.1%) compared with
eGFRmdrd (4 patients, 7.5%), eGFRepi (3 patients, 5.7%), or
eGFRmix (8 patients, 15.1%). Among 20 diabetic patients, we
observed a similar trend. The prevalence of L-GFR was 8
patients (40.0%) based on eGFRcys, 2 patients (10.0%) based
on eGFRmdrd, 2 patients (10.0%) based on eGFRepi, and 3
patients (15%) based on eGFRmix. However, the differences
with eGFRcys did not reach formal statistical significance (𝑃 ≥
0.075).
Finally, we explored whether an eGFRcys below 60mL/
min/1.73m2 improved the differentiation betweennormoten-
sion versus hypertension or between people without or with
diabetes mellitus based on the other estimates of GFR.
However, the classification based on eGFRcys did not improve
IDI (𝑃 ≥ 0.53) or NRI (𝑃 ≥ 0.24) for hypertension or IDI
(𝑃 ≥ 0.37) or NRI (𝑃 ≥ 0.24) for diabetes mellitus.
4. Discussion
In our current analysis, we compared the performance of
the equations based on cystatin C and creatinine to estimate
GFR in a Uruguayan population sample. The Uruguayan
population has been considered as mainly European descent,
with a negligible Native American or African contributions.
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Figure 1: Bland and Altman plots comparing eGFRmdrd, eGFRepi, and eGFRmix, with eGFRcys as the referent method. eGFRcys, eGFRmdrd,
eGFRepi, and eGFRmix indicate estimated glomerular filtration rate derived from serum cystatin C, from serum creatinine according to the
Modification of Diet in Renal Disease or the Chronic Kidney Disease Epidemiology Collaboration equations, or from both serum cystatin C
and creatinine. 𝑅 indicate the intraclass correlation coefficient. 𝑃 denotes the significance level.
However, based on serological andmolecularmarkers, recent
studies demonstrate that Native American and African had
an important influence in the conformation of the present one
[24–26].
The key finding was that eGFRcys provides lower
estimates in comparison with creatinine based equations
(eGFRmdrd and eGFRepi). Mean eGFR was 80.0, 89.7, 91.5,
and 85.6mL/min/1.73m2 for eGFRcys, eGFRmdrd, eGFRepi,
and eGFRmix, respectively. Thus, the prevalence of L-GFR,
was higher when derived from equations involving cystatin
C (eGFRcys and eGFRmix) than when derived from creatinine
based equations. The prevalence of L-GFR using eGFRcys,
eGFRmdrd, eGFRepi, and eGFRmix was 21.8%, 5.9%, 3.4%,
and 11.8%, respectively. In categorical analysis, the agreement
between cystatin-based (eGFRcys) equations and creatinine-
based equations (eGFRmdrd and eGFRepi) to detect eGFR
under 60mL/min/1.73m2 was low.
Over the past, many reports highlighted the ability of
cystatin C to detect renal disease early in different settings
[27–31]. Several researchers reported cystatin C outperforms
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Table 2: Differences between various estimates of GFR with eGFR derived from serum cystatin C as referent method.
Group 𝑁 Difference in estimates of glomerular filtration rate (mL/min/1.73m
2)
eGFRmdrd eGFRepi eGFRmix
All participants 119 9.7 (5.3–14.0)§ 11.5 (8.2–14.9)§ 5.6 (4.1–7.0)§
Women 68 11.3 (4.7–17.9)‡ 13.7 (8.7–18.6)§ 6.4 (4.3–8.5)§
Men 51 7.5 (2.1–12.9)§ 8.7 (4.3–12.9)‡ 4.5 (2.6–6.3)§
<60 years 57 3.2 (−4.1–10.4) 9.6 (3.9–15.3)† 4.5 (2.1–6.8)‡
≥60 years 62 15.6 (10.8–20.5)§ 13.3 (9.4–17.2)§ 6.6 (4.9–8.3)§
Normotension 66 8.1 (0.9–15.3)∗ 10.4 (4.9–15.8)‡ 4.9 (2.6–7.3)§
Hypertension 53 11.6 (7.3–15.9)§ 12.9 (9.5–16.4)§ 6.3 (4.8–7.7)§
No diabetes 99 9.5 (4.7–14.4)‡ 11.9 (8.3–15.7)§ 5.7 (4.1–7.3)§
Diabetes 20 10.3 (−0.7–21.3) 9.4 (0.7–18.1)∗ 4.9 (1.4–8.4)†
eGFRmdrd, eGFRepi, and eGFRmix indicate estimated glomerular filtration rate from serum creatinine according to the Modification of Diet in Renal Disease
or the Chronic Kidney Disease Epidemiology Collaboration equations or from both serum cystatin C and creatinine. Differences were computed as eGFRmdrd,
eGFRepi, or eGFRmix minus GFR estimated from serum cystatin C (eGFRcys). The values between brackets were the 95% confidence intervals (mean ± 1.96
standard errors).𝑁 indicates the number of participants. Significance of the difference with eGFRcys:
∗
𝑃 ≤ 0.05; †𝑃 ≤ 0.01; ‡𝑃 ≤ 0.001; §𝑃 ≤ 0.0001.
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Figure 2:Mean andmean ±1 standard deviation interval of eGFRcys
(X), eGFRmdrd (◼), eGFRepi (󳵳), and eGFRmix (e) across fourths of
the distribution of eGFRcys. The abbreviations eGFRcys, eGFRmdrd,
eGFRepi, and eGFRmix indicate estimated glomerular filtration rate
derived from serum cystatin C, from serum creatinine according to
the Modification of Diet in Renal Disease or the Chronic Kidney
Disease Epidemiology Collaboration equations, or from both serum
cystatin C and creatinine. eGFRmdrd, eGFRepi, and eGFRmix were
consistently higher (𝑃 < 0.0001) than eGFRcys except in the highest
category of eGFRcys (𝑃 = 0.25).
serum creatinine in the early diagnosis of acute kidney injury
[32, 33] or its prognosis [34]. In line with our results, other
investigators reported lower estimates of eGFR using cystatin
C as biomarker [6, 35, 36]. In contrast, in a Belgian population
sample [𝑛 = 4,189], Delanaye and colleagues report that the
prevalence of eGFR below 60mL/min/1.73m2 using eGFRcys,
eGFRmdrd, eGFRepi, and eGFRmix was 4.7%, 13.0%, 9.8%, and
5.0%, respectively [37]. In a recent report, among 394 old
(>74 y) subjects and patients from England, Kilbride and
colleagues describe lower eGFRcys (55.2mL/min/1.73m
2)
in comparison with creatinine based equations (eGFRmdrd,
57.6mL/min/1.73m2; eGFRepi, 57.0mL/min/1.73m
2) [38].
Grams and colleagues [36], analyzing representative subsam-
ples of the adult participants in the National Health and
Nutrition Examination Surveys (NHANES; 1988–1994 [𝑛 =
15,133] and 1999–2002 [𝑛 = 8,238]), observed slightly higher
eGFR using cystatin C than creatinine equations (102.9 versus
99.4mL/min/1.73m2). However, in line with our results, the
proportion of subjects with eGFR below 60mL/min/1.73m2
was larger if derived from cystatin C than creatinine (5.5%
versus 4.7%).More recently, Tsai and colleagues [35] reported
similar results in diabetic patients enrolled in NHANES. The
mean eGFRcys was 100.7mL/min/1.73m
2 and the eGFRepi
was 95.1mL/min/1.73m2 while the proportions of patients
with eGFR below 60mL/min/1.73m2 were 22.0% and 16.5%,
respectively. Pattaro and colleagues also found similar results
in a cross-sectional analysis of a population from three alpine
villages [39]. Finally, in a recent meta-analysis Shlipak and
colleagues noticed similar mean eGFRcys and eGFRepi esti-
mates while the proportion of subjects under the threshold to
define CKD was 13.7 and 9.7mL/min/1.73m2 using cystatin
and creatinine based equations, respectively [6].
In line with our current results, Delanaye described low
agreement between creatinine and cystatin C based formulas
(kappa statistic 0.32 [eGFRcys versus eGFRmdrd] and 0.39
[eGFRcys versus eGFRepi]) [37]. In this Belgian study, the
percentage of discordant subjects estimated by eGFRmdrd,
eGFRepi, and eGFRmix was 11.2%, 8.29%, and 2.71%, taking
eGFRcys as reference.
How to explain the discrepancies between cystatin C and
creatinine based equations? We first discarded all potential
sources of preanalytical and analytical errors. We analysed
creatinine in fresh serum samples and cystatin C in sam-
ples that were kept frozen at −80∘C. Over a period of 10
years, a decay in cystatin C levels occurs using a particle-
enhanced nephelometric assay (PENIA) [40]. Such decay is
not observed if one uses the more robust particle-enhanced
turbidimetric assay (PETIA). Furthermore, our samples were
analysed within one year after blood collection and were
processed with calibration each time. We used a validated
method [40, 41] and reagents (Tina-quant Cystatin C Gen.
2) standardized to the international reference material ERM-
DA471/IFCC, as currently recommended for the use ofCKD-
EPI equations [3, 7]. Studies of bias (mean difference from
reference method) usually overestimated GFR compared
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Table 3: Prevalence by categories of eGFR according to the stages of chronic kidney disease, for equation to estimate the GFR.
Stage of kidney disease Estimated glomerular filtration rate 𝑃
eGFRcys eGFRmdrd eGFRepi eGFRmix
<60mL/min/1.73m2 26 (21.8) 7 (5.9)‡ 4 (3.4)§ 14 (11.8)∗ <0.0001
60–89mL/min/1.73m2 56 (47.1) 59 (49.6) 51 (42.8) 58 (48.7) 0.73
≥90mL/min/1.73m2 37 (31.1) 53 (44.5)∗ 64 (53.8)‡ 47 (39.5) 0.004
eGFRcys, eGFRmdrd, eGFRepi, and eGFRmix indicate estimated glomerular filtration rate derived from serum cystatin C, from serum creatinine according to
theModification of Diet in Renal Disease or the Chronic Kidney Disease Epidemiology Collaboration equations or from both serum cystatin C and creatinine.
Values are number of participants (%). 𝑃 values are for the overall difference across four estimates of glomerular filtration rate. Significance of the difference
with eGFRcys:
∗
𝑃 ≤ 0.05; †𝑃 ≤ 0.01; ‡𝑃 ≤ 0.001; §𝑃 ≤ 0.0001.
with the reference when using MDRD (range −1.0 to +3.5)
or CKD-EPI (range −0.23 to +4.4) and underestimated when
using cystatin C based equations (range −5.7 to −1.2) [38, 42–
44]. Fewer studies showed a lower positive bias of cystatin C
than CKD-EPI based equations [7, 45].
Several epidemiological studies showed that cystatin C
is a better predictor of outcomes in coronary heart disease,
acute coronary syndrome, and heart failure, independently
of serum creatinine and GFR estimation [6, 46–49]. Further-
more, Peralta et al. demonstrated in a large and ethnically
diverse population that subjects with decreased eGFRcys had
elevated risk of death, cardiovascular disease, and heart
failure and had an elevated risk of kidney failure [50, 51]. In
keeping with these studies, our population sample had a high
cardiovascular risk profile. We found a higher prevalence of
L-GFR among hypertensive subjects (𝑃 < 0.001) if they
were categorized based on eGFRcys (32.1%) than on eGFRepi
(5.7%) with a similar but not significant trend among the
few diabetics patients. However, when computing IDI and
NRI we did not observe significant differences between the
various estimates of eGFR for hypertension or diabetes (𝑃 ≥
0.24). In accordance with previous reports [48, 52–54], the
prevalence of hypertension (𝑃 = 0.27) and age (𝑃 < 0.0001),
systolic blood pressure (𝑃 < 0.01), cholesterol (𝑃 = 0.004),
aortic pulse wave velocity (𝑃 < 0.0001), and the central
augmentation index (𝑃 < 0.0001) increased with lower
categories of eGFRcys (Table 1).
Our results should be interpreted within the limitation of
the study. First, we did not have a reliable “gold standard”
due to the variability in 24 h urine collections. Performing
inulin or iothalamate clearance implies invasive and tedious
procedures that are not suitable for our population study.
Second, participants of the studymay not be representative of
the Uruguayan population, because we randomly sampled a
neighbourhood and our participants had a higher cardiovas-
cular risk profile than the general population ofUruguay [55].
Finally, the small sample size of our population is a limiting
factor to analyse specific subgroups of participants. However,
the number of participants is large enough to describe the
difference between eGFR estimating equations.
In conclusion, to our knowledge, this is the first report
based on a population from South America comparing to
the performance of eGFR equations based on cystatin C and
creatinine.We confirm discrepancies in eGFR using equation
based on different biomarkers, particularly in the range
of GFR under 60mL/min/1.73m2. Generally, the equation
based on cystatin C, compared with creatinine, results in
lower eGFR values and, therefore, higher estimates of the
prevalence of eGFR below 60mL/min/1.73m2.
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 Table S1.  Estimated glomerular filtration rate derived from serum cystatin C and/or creatinine  
Estimated 
glomerular  
filtration rate  
Cystatin C  
(mg/L)  
Creatinine  
(mg/dL)  
Equation  
eGFRcys     
Women  ≤0.8  133  (Scys / 0.8)
–0.499
  0.996
Age 
x 0.932  
 >0.8  133  (Scys / 0.8)
–1.328
  0.996
Age 
x 0.932  
Men  ≤0.8  133  (Scys / 0.8)
–0.499
  0.996
Age 
 
 >0.8  133  (Scys / 0.8)
–1.328
  0.996
Age 
 
eGFRmdrd     
Women    175  (Scr)
–1.154
  Age
–0.203
  0.742 [  1.212 if black]  
Men    175  (Scr)
–1.154
  Age
–0.203
 [ 1.212 if black]  
eGFRepi      
Women   ≤0.7 144  (Scr/0.7)
–0.329
  0.993
Age 
[ 1.159 if black]  
  >0.7 144  (Scr/0.7)
–1.209
  0.993
Age 
[ 1.159 if black]  
Men   ≤0.9 141  (Scr/0.9)
–0.411
  0.993
Age 
[  1.159 if black]  
  >0.9 141  (Scr/0.9)
–1.209
  0.993
Age 
[  1.159 if black]  
eGFRmix     
Women  ≤0.8 ≤0.7 130  (Scr/0.7)
–0.248
  (Scys/0.8)
–0.375
  0.995
Age
 [ 1.08 if black]  
  >0.7 130  (Scr/0.7)
–0.601
  (Scys/0.8)
–0.375
  0.995
Age
 [ 1.08 if black]  
 >0.8 ≤0.7 130  (Scr/0.7)
–0.248
  (Scys/0.8)
–0.711
  0.995
Age
 [ 1.08 if black]  
  >0.7 130  (Scr/0.7)
 –0.611
  (Scys/0.8)
–0.711
  0.995
Age
 [ 1.08 if black]  
Men  ≤0.8 ≤0.9 135  (Scr/0.9)
 –0.207
  (Scys/0.8)
–0.375
  0.995
Age
 [ 1.08 if black]  
  >0.9 135  (Scr/0.9)
 –0.601
  (Scys/0.8)
–0.375
  0.995
Age
 [ 1.08 if black]  
 >0.8 ≤0.9 135  (Scr/0.9)
 –0.207
  (Scys/0.8)
–0.711
  0.995
Age
 [ 1.08 if black]  
  >0.9 135  (Scr/0.9)
 –0.601
  (Scys/0.8)
–0.711
  0.995
Age
 [ 1.08 if black]  
Abbreviations: eGFRcys, eGFRmdrd, eGFRepi, eGFRmix indicate estimated glomerular filtration rate derived from serum 
cystatin C, from serum creatinine according to the Modification of Diet in Renal Disease or the Chronic Kidney Disease 
Epidemiology Collaboration equations, or from bot serum cystatin C and creatinine.  Scys and Scr indicate serum cystatin C 
and serum creatinine, respectively.
 Table S2.   Differences between various estimates of GFR with eGFR derived from serum cystatin C as 
referent method  
Group  N  
Difference in estimates of glomerular filtration rate  
(mL/min/1.73m2)  
eGFRmdrd  eGFRepi  eGFRmix  
All participants  119  9.7 (-38.4–57.8)§  11.5 (-25.5–48.5)§  5.6 (-10.2–21.4)§  
Women  68  11.3 (-43.1–65.7)‡ 13.7 (-27.1–54.5)§  6.4 (-11.2–24.0)§  
Men  51  7.5 (-30.9–45.9)§ 8.7 (-22.1–39.5)‡  4.5 (-8.7–17.7)§  
<60 years  57  3.2 (-51.4–57.8)  9.6 (-33.2–52.4)†  4.5 (-13.5–22.5)‡  
≥60 years  62  15.6 (-22.4–53.6)§  13.3 (-17.5–44.1)§  6.6 (-6.8–20.0)§  
Normotension  66  8.1 (-50.3–66.5)*  10.4 (-34.0–54.8)‡  4.9 (-14.1–23.9)§  
Hypertension  53  11.6 (-19.8–43.0)§  12.9 (-12.1–37.9)§  6.3 (-4.3–16.9)§  
No diabetes  99  9.5 (-39.1–58.1)‡ 11.9 -25.3–49.1) § 5.7 (-10.3–21.7)§  
Diabetes  20  10.3 (-36.7–57.3)  9.4 (-27.6–46.4)*  4.9 (-10.1–19.9)†  
Abbreviations: eGFRmdrd, eGFRepi, eGFRmix indicate estimated glomerular filtration rate from serum creatinine according 
to the Modification of Diet in Renal Disease or the Chronic Kidney Disease Epidemiology Collaboration equations, or from 
both serum cystatin C and creatinine.  Differences were computed as eGFRmdrd, eGFRepi, or  eGFRmix  minus GFR 
estimated from serum cystatin C (eGFRcys).  Values between brackets are the mean ± 2 SD intervals.  N indicates the 
number of participants.  Significance of the difference with eGFRcys: * P≤0.05; † P≤0.01; ‡ P≤0.001; § P≤0.0001.  
 Table S3.   Absolute bias between various estimates of GFR and the eGFR derived from serum cystatin C as 
referent method.  
Group  N  
Absolute bias in estimates of glomerular filtration rate  
(mL/min/1.73m2)  
eGFRmdrd  eGFRepi  eGFRmix  
All participants  119  15.6 (2.9–53.0) 17.0 (1.1–46.0)  7.8 (0.9–18.6)  
Women  68  17.4 (2.9–55.4) 18.5 (2.6–46.7)  8.9 (1.3–20.5)  
Men  51  10.9 (2.8–44.9) 12.2 (0.4–33.4) 5.7 (0.7–14.0)  
<60 years  57  10.9 (0.4–64.7) 16.2 (1.0–53.7)  6.6 (1.0–24.5)  
≥60 years  62  17.4 (3.8–44.9) 17.8 (1.3–33.4)  8.4 (0.9–15.8)  
Normotension  66  19.4 (2.9–58.9) 18.1 (1.2–48.0)  8.3 (1.0–20.5)  
Hypertension  53  12.3 (1.6–40.4) 15.6 (1.1–28.4)  6.7 (0.9–12.1)  
No diabetes  99  15.7 (1.6–55.4) 17.4 (1.2–46.0) 8.1 (1.0–19.1)  
Diabetes  20  14.1 (3.5–52.2) 14.6 (0.7–44.3)  7.2 (0.5–17.2)  
Values are median and the 5
th
 to 95
th
 interval between brackets.  N indicates the number of participants.  Abbreviations: 
eGFRmdrd, eGFRepi, eGFRmix indicate estimated glomerular filtration rate from serum creatinine according to the 
Modification of Diet in Renal Disease or the Chronic Kidney Disease Epidemiology Collaboration equations, or from both 
serum cystatin C and creatinine.  Absolute bias were computed as the absolute difference between eGFRmdrd, eGFRepi, or  
eGFRmix  minus GFR estimated from serum cystatin C (eGFRcys). 
 Table S4.   Estimated Glomerular Filtration Rate by Racial Parental Background of the Participants.  
Group  N  
 glomerular filtration rate  
(mL/min/1.73m2)  
eGFRcys eGFRmdrd  eGFRepi  eGFRmix  
All participants  119  80.0±23.8 89.7±22.5 91.5±19.0  85.6±20.2 
Coincident white 82 78.1±25.7 89.6±23.5 90.7±19.7 84.1±21.9 
White-Black  17 88.3±14.3 99.7±23.4 100.2±14.5 94.6±14.2 
White-Native American 16 77.3±14.4 81.4±18.1 86.9±21.0 81.3±15.6 
Black-Native American 4 82.1±7.1 88.8±5.4 95.4±13.7 88.9±9.3 
Values are mean ± SD. Abbreviations: eGFRmdrd, eGFRepi, eGFRcys, eGFRmix indicate estimated glomerular filtration rate 
from serum creatinine according to the Modification of Diet in Renal Disease or the Chronic Kidney Disease Epidemiology 
Collaboration equations, or from both serum cystatin C and creatinine. 
